Analyst Update: Mobileye NV, Whiting Petroleum Corp, and Vascular Biogenics Ltd

Analysts revised their ratings and price targets on Mobileye NV (NYSE:MBLY), Whiting Petroleum Corp (NYSE:WLL), and Vascular Biogenics Ltd (NASDAQ:VBLT)

by Josh Selway

Published on Jun 28, 2016 at 2:10 PM

Analysts are weighing in on automotive tech specialist Mobileye NV (NYSE:MBLY), oil-and-gas stock Whiting Petroleum Corp (NYSE:WLL), and biotech issue Vascular Biogenics Ltd (NASDAQ:VBLT)Here's a quick roundup of today's brokerage notes on MBLY, WLL, and VBLT.

  • MBLY is up 0.9% at $40.14, shrugging off a downgrade to "neutral" at Goldman Sachs, which also cut its price target to $40. The stock is down 24% year-over-year, but has seen strong support from its rising 100-day moving average in recent months. While short interest has been rising on Mobileye NV, analysts remain upbeat. In fact, 10 out of 12 brokerage firms recommend buying the shares. 
  • WLL is also overcoming negative analyst attention, as KLR Group, SunTrust Robinson, and Wunderlich all lowered their price targets on the stock, with the latter setting the lowest mark of $11. This is still a premium to current levels, though, with Whiting Petroleum Corp last seen at $8.97 -- 4.9% higher on the day. The stock recently gave up its perch above the $10 level, falling into negative year-to-date territory, and options traders have been betting on more downside. Specifically, WLL's 10-day put/call volume ratio at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) stands at 2.55 -- just 5 percentage points from a 12-month high. 
  • A fresh "buy" rating and $11 price target from H.C. Wainwright has VBLT up 5.1% at $4.15. The analysts added "VBL's gene therapy has the advantages of better tissue-specific activity, lower toxicity, simpler dosing regimen, and is also able to incite a potent immune response against cancer." The bullish note is far from unusual for the stock, as every analyst that covers VBLT rates it a "strong buy." Looking back, Vascular Biogenics Ltd exploded higher earlier this month on upbeat drug news, but has since given back almost all those gains to sit in a 21% year-to-date hole -- though that's still better than the performance of this struggling sector peer

For other stocks in analysts' crosshairs, read Analyst Upgrades: Apple Inc., AstraZeneca plc (ADR), and Dicks Sporting Goods Inc and Analyst Downgrades: AT&T Inc., Sonic Corporation, and Southwest Airlines Co.


A Schaeffer's exclusive

6 Sectors for Summer

Access your FREE insider report before it's too late!


  
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


The Next Big Player in U.S. MJ Boom
Most pure-play marijuana stocks in the U.S. trade on the Over-the-Counter stock exchange.
Planet Fitness Stock Lifted Amid Re-Opening Optimism
Planet Fitness reopened around 800 facilities in North America
Coffee Stock Drops Despite Cost-Cutting Initiatives
Starbucks asked employees to further limit working hours or take unpaid leave
The Big Bankruptcy You Should Be Afraid Of
Porter Stansberry is making a concerning prediction.